California State Teachers Retirement System Trims Position in Alexion Pharmaceuticals, Inc. (ALXN)

California State Teachers Retirement System cut its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 404,755 shares of the biopharmaceutical company’s stock after selling 27,469 shares during the quarter. California State Teachers Retirement System owned 0.18% of Alexion Pharmaceuticals worth $49,246,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the stock. BlackRock Inc. raised its holdings in shares of Alexion Pharmaceuticals by 7.0% in the second quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock worth $2,424,428,000 after acquiring an additional 1,298,185 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Alexion Pharmaceuticals by 2.2% in the second quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock worth $1,798,992,000 after acquiring an additional 318,375 shares during the last quarter. State Street Corp raised its holdings in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock worth $1,443,099,000 after acquiring an additional 561,962 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Alexion Pharmaceuticals by 0.4% in the second quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock worth $751,363,000 after acquiring an additional 25,724 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Alexion Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock worth $407,573,000 after acquiring an additional 64,800 shares during the last quarter. 94.25% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on the company. UBS AG reissued a “buy” rating and issued a $108.00 price target on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th. BidaskClub cut Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, August 14th. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target for the company in a report on Wednesday, August 2nd. J P Morgan Chase & Co reissued a “hold” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th. Finally, Evercore ISI assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 price target for the company. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $154.56.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. During the same period last year, the company earned $1.13 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% compared to the same quarter last year.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the transaction, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the transaction, the director now owns 5,480 shares in the company, valued at $799,038.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,190 shares of company stock worth $2,433,669. Corporate insiders own 4.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.themarketsdaily.com/2017/10/12/california-state-teachers-retirement-system-trims-position-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply